<DOC>
	<DOCNO>NCT00834041</DOCNO>
	<brief_summary>This first open-label study pediatric population design evaluate aliskiren safety pharmacokinetics single multiple dose 6-17 year old child hypertension .</brief_summary>
	<brief_title>A Study Evaluate Safety/Tolerability Pharmacokinetics Aliskiren Hypertensive Pediatric Adolescent Patients 6-17 Years Age</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<criteria>Male female , 617 year age Documented history hypertension define National High Blood Pressure Education Program Working Group High Blood Pressure Children Adolescents ( 2004 ) Must ≥ 21.0 kg ≤ 100.0 kg randomization Able safely wash previous antihypertensive therapy 12 week Body weight &lt; 21 kg ( 45 lb ) &gt; 100 kg ( 220 lb ) Inability discontinue prior antihypertensive medication require washout period Any clinically significant abnormality clinically noteworthy abnormal laboratory value Renal artery stenosis Current diagnosis heart failure ( NYHA Class IIIV ) msSBP ≥ 25 % 95th percentile age , gender , height Visit 2 Second third degree heart block without pacemaker Atrial fibrillation atrial flutter Visit 1 , potentially life threaten symptomatic arrhythmia 12 month prior Visit 1 Evidence current symptomatic valvular disease Other protocoldefined inclusion/exclusion criterion apply study .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>aliskiren</keyword>
	<keyword>pediatric</keyword>
	<keyword>hypertension</keyword>
	<keyword>pharmacokinetics ( PK )</keyword>
	<keyword>pharmacodynamics ( PD )</keyword>
	<keyword>plasma renin activity</keyword>
	<keyword>mini-tablet formulation</keyword>
</DOC>